Why the study?
Does high residual platelet reactivity to ADP predict cardiovascular death and nonfatal MI in acute coronary syndrome patients undergoing PCI?
Population
683 patients with acute coronary syndrome undergoing dual-antiplatelet therapy who underwent percutaneous…
Comparison
High residual platelet reactivity to ADP… vs Low residual platelet reactivity
Design
Cohort
Follow-up
12 months
Authors
Loading...
May support risk stratification in ACS-PCI patients; leaves open whether RPR-guided therapy improves outcomes.
Does high residual platelet reactivity to ADP predict cardiovascular death and nonfatal MI in acute coronary syndrome patients undergoing PCI?
High residual platelet reactivity to ADP measured by a point-of-care assay identifies ACS patients undergoing PCI who are at increased risk for 12-month cardiovascular death and nonfatal MI.
Marcucci et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: